Previous 10 | Next 10 |
PAVmed Provides Business Update and First Quarter Financial Results PR Newswire EsoGuard ® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference cal...
2023-05-16 02:41:11 ET Lucid Diagnostics press release ( NASDAQ: LUCD ): Q1 Non-GAAP EPS of -$0.24 beats by $0.06 . Revenue of $0.4M (+100.0% Y/Y) beats by $0.17M . Lucid had cash and cash equivalents of $39.5 million as of March 31, 2023, compared to $22.5 mil...
Lucid Diagnostics Provides Business Update and First Quarter Financial Results PR Newswire EsoGuard ® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16 th at 8:30 AM EST...
2023-05-12 15:00:44 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference PR Newswire EsoGuard ® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in m...
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President PR Newswire Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK , April 25, 2023 /PRNewswire/ -- PAVmed Inc....
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS PR Newswire Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m....
Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions PR Newswire Lucid's CLIA laboratory, which performs its EsoGuard test, operates within Noridian's jurisdictio...
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diag...
2023-03-31 14:17:57 ET Shares of medical diagnostics company Lucid Diagnostics ( NASDAQ: LUCD ) rose ~6% on Friday after Medicare Administrative Contractor Palmetto GBA finalized Local Coverage Determination for molecular testing of certain upper gastrointestinal lesions. ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...